REBIF Drug Profile

Summary for Tradename: REBIF

High Confidence Patents:	6
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for REBIF

See drug prices for REBIF

Pharmacology for REBIF

Established Pharmacologic Class	Interferon beta
Chemical Structure	Interferon-beta

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for REBIF Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for REBIF Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780		2007-10-30	DrugPatentWatch analysis and company disclosures
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780		2021-10-25	DrugPatentWatch analysis and company disclosures
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780		2024-03-16	DrugPatentWatch analysis and company disclosures
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780		2026-09-15	DrugPatentWatch analysis and company disclosures
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780		2024-07-16	DrugPatentWatch analysis and company disclosures
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780		2031-09-12	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for REBIF Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780		2034-01-08	Patent claims search
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780		2033-07-24	Patent claims search
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780		2036-10-04	Patent claims search
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780		2037-02-24	Patent claims search
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780		2037-02-13	Patent claims search
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780		2036-06-14	Patent claims search
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780		2036-11-18	Patent claims search

International Patents for REBIF

Country	Patent Number	Estimated Expiration
Georgia, Republic of	P20074024
Luxembourg	93162
Japan	3158952
South Africa	200406555
Brazil	8102922
Montenegro	P35608
Slovenia	8110859

Supplementary Protection Certificates for REBIF

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
132016000087753	Italy		PRODUCT NAME: PEGINTERFERON BETA-1A O UN PRODOTTO BIOSIMILARE(PLEGRIDY); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/934, 20140723
2016C/040	Belgium		PRODUCT NAME: PEGINTERFERON BETA-1A; AUTHORISATION NUMBER AND DATE: EU/1/14/934 20140723
CR 2016 00035	Denmark		PRODUCT NAME: PEGINTERFERON BETA-1A; REG. NO/DATE: EU/1/14/934 20140723
300826	Netherlands		PRODUCT NAME: PEGINTERFERON BETA-1A; REGISTRATION NO/DATE: EU/1/14/934 20140723
286 50007-2016	Slovakia		PRODUCT NAME: PEGINTERFERON BETA-1A; REGISTRATION NO/DATE: EU/1/14/934 20140723
CA 2016 00035	Denmark		PRODUCT NAME: PEGINTERFERON BETA-1A ELLER ET BIOSIMILAERT PRODUKT IFOELGE ARTIKEL 10(4) I DIREKTIV 2001/83/EC SOM BESKYTTET I GRUNDPATENTET; REG. NO/DATE: EU/1/14/934 20140723
590	Finland

REBIF: Market dynamics and financial trajectory for the biologic

Last updated: April 25, 2026

What is REBIF and where does it sit in the MS market?

REBIF is an injectable disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). It is a branded interferon beta-1a product in the interferon class, targeting reduction of relapse activity and slowing of disease progression.

In the relapsing MS market, REBIF competes in a crowded field dominated by newer high-efficacy categories, including oral small molecules (notably S1P modulators) and high-efficacy monoclonal antibodies (for example, anti-CD20 agents). Interferons remain clinically established but face sustained share pressure as prescribers migrate to therapies with stronger efficacy metrics, dosing convenience, or patient preference profiles.

How has demand trended versus newer MS brands?

The economics of REBIF have been shaped by two structural forces:

• Efficacy and convenience migration: High-efficacy mechanisms and less frequent dosing regimens have pulled new starts away from interferons in multiple geographies.
• Patent and lifecycle pressure: As with most mature biologics, brand economics deteriorate as competitive offerings expand and payer policies tighten.

REBIF’s financial trajectory follows a typical mature branded biologic pattern in MS:

• Early years: growth and broad uptake
• Mid-stage: plateau as head-to-head retention rises
• Later stage: contraction as high-efficacy entrants gain share

What are the key market dynamics affecting REBIF pricing and access?

1) Payer controls and formulary selectivity

MS coverage increasingly reflects step-editing, prior authorization, and criteria that favor higher-efficacy options for eligible subgroups. That dynamic typically reduces utilization for mature interferons, even where clinical differentiation remains meaningful.

2) Net price pressure from competition

Interferon competitors and biosimilar erosion risks (within interferon beta classes) tend to compress net price even if list prices remain stable. In practice, contracting and rebates drive downward net revenue.

3) Switching behavior and prescriber preferences

Switching away from interferons often occurs when:

• disease activity persists despite treatment
• tolerability issues occur (notably flu-like symptoms and injection burden)
• patient access improves for alternative mechanisms

4) Drug delivery and tolerability as adoption levers

REBIF’s subcutaneous interferon beta formulation and dosing schedule have historically been a barrier to patient preference compared with:

• oral MS medicines
• higher efficacy injectables with less frequent administration

How has REBIF’s financial trajectory evolved across major reporting periods?

Reliable, decision-grade “financial trajectory” requires audited revenue disclosures at the product level. The provided source set contains only qualitative market context and does not include REBIF’s standalone revenue lines or segment reporting breakouts sufficient to produce a complete numeric trajectory.

Because the request is explicitly for market dynamics and financial trajectory, including hard numbers (e.g., annual revenue, growth rates, operating income contribution, marketing spend trends), producing a complete and accurate answer without audited figures is not possible from the information available here.

What can be concluded about REBIF’s commercial position based on available disclosures?

Even without product-level revenue tables, the market positioning is clear:

• Class: interferon beta-1a injectable DMT (mature biologic segment)
• Competitive structure: increasing dominance of oral and monoclonal antibody high-efficacy regimens
• Commercial pattern: high likelihood of declining or stagnant unit demand and net pricing pressure typical of mature MS brands facing superior-efficacy entrants

For business planning, the implication is a continued need to defend:

• formulary inclusion in targeted payer segments
• continuity treatment cohorts
• cost-effectiveness narratives versus newer mechanisms on specific eligibility profiles

What are the dominant drivers of REBIF performance going forward?

Demand drivers

• retention of existing interferon cohorts (treatment continuity)
• stability in relapse rates for controlled patients
• constrained switching for patients stable on therapy

Headwinds

• persistent migration to higher-efficacy therapies
• payer-led restriction of interferons in higher-activity disease
• net price compression via contracting dynamics

Strategic levers

• patient support programs to improve adherence and persistence
• payer contracting using real-world retention and stability endpoints
• evidence packages around tolerability management and adherence outcomes

What is the competitive landscape REBIF faces?

REBIF competes broadly across:

• other interferons (and potential biosimilar equivalents where applicable)
• glatiramer acetate
• oral S1P modulators
• injectable and infusion monoclonal antibody therapies

The net effect is a shrinking addressable “new start” pool for interferons and increased concentration of prescribing into stable long-term patients.

Commercial outlook: what trajectory is most consistent with the observed MS market?

Given the structural MS market shift toward high-efficacy and oral dosing convenience, the most consistent trajectory for a mature interferon like REBIF is:

• declining or stagnant volume
• declining or volatile net price
• continued pressure on incremental growth

This pattern typically results in flat-to-down revenue trends over multi-year periods, with profitability depending on manufacturing scale, marketing efficiency, and legal or lifecycle events affecting competition and access.

Key Takeaways

• REBIF is a mature interferon beta-1a DMT in relapsing MS with access shaped by payer selectivity and competitive share shifts.
• High-efficacy mechanisms and oral convenience have driven ongoing migration away from interferons toward newer categories.
• Without audited, product-level financial disclosures in the provided materials, a numeric annual “financial trajectory” cannot be stated without risking factual error.
• Forward performance is most likely determined by treatment retention, contracting strength, and how payers place interferons within step-editing frameworks.

FAQs

1) Is REBIF considered a high-efficacy MS therapy?
REBIF is an established interferon beta-1a DMT. In MS market terms, interferons are generally positioned below newer high-efficacy mechanisms.

2) What most directly pressures REBIF demand?
Share shift to high-efficacy monoclonal antibodies and oral S1P modulators, plus payer restrictions that limit interferons for higher-activity disease.

3) How do payers influence REBIF performance?
Through formulary placement, prior authorization, step-editing criteria, and negotiated rebates that typically compress net pricing for mature brands.

4) What protects REBIF against faster decline?
Treatment retention among patients stable on therapy and reduced switching when disease control is maintained.

5) What should an investor monitor for REBIF?
Formulary status in key markets, net price trends via contracting, and persistence (real-world discontinuation rates) among existing cohorts.

References

[1] Bloomberg Second Edition. Drug and Biologics Market Coverage (MS therapeutics overview). Bloomberg L.P.
[2] FDA. Labeling information for interferon beta products in multiple sclerosis (class-level guidance and clinical context). U.S. Food and Drug Administration.
[3] EMA. Interferon beta product information and clinical use context for multiple sclerosis. European Medicines Agency.